Jump to content


Biomarker for Diffuse Scleroderma skin has been discovered!


Photo

Efficacy and safety of intravenous cyclophosphamide pulse therapy with oral prednisolone in the treatment of interstitial lung disease (ILD) with systemic sclerosis:


  • Please log in to reply
No replies to this topic

#1 Jeannie McClelland

Jeannie McClelland

    Senior Gold Member

  • ISN Support Specialists
  • PipPipPipPipPipPipPipPipPipPip
  • 1,706 posts
  • Location:in the Rocky Mountains of the USA

Posted 16 April 2011 - 09:03 AM

Efficacy and safety of intravenous cyclophosphamide pulse therapy with oral prednisolone in the treatment of interstitial lung disease (ILD) with systemic sclerosis: 4-year follow-up This long observational study for 48 months showed the efficacy of intravenous cyclophosphamide (IVCY) pulse therapy with prednisolone (PSL) for active alveolitis in the first year. However, because five patients had recurrence of ILD more than 1 year after the treatment, it would be necessary to consider maintenance therapy for ILD beyond 1 year. Akiko Tochimoto, Modern Rheumatology, 15 January 2011. (Also see: Treatments for Pulmonary Fibrosis - cyclophosphamide)

This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.


Jeannie McClelland
(Retired) ISN Director of Support Services
(Retired) ISN Sclero Forums Manager
(Retired) ISN Blog Manager
(Retired) ISN Assistant News Guide
(Retired) ISN Artist
International Scleroderma Network